ACP
GALT icon

Argyle Capital Partners’s Galectin Therapeutics GALT Stock Holding History

Argyle Capital Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.1K Hold
13,375
– – 0.04% 177
2026
Q1 		$37.3K Hold
13,375
– – 0.03% 160
2025
Q4 		$55.6K Hold
13,375
– – 0.04% 157
2025
Q3 		$56.6K Hold
13,375
– – 0.04% 165
2025
Q2 		$28.2K Hold
13,375
– – 0.02% 150
2025
Q1 		$16.3K Hold
13,375
– – 0.01% 138
2024
Q4 		$17.3K Buy
+13,375
New +$32.1K 0.01% 141

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Argyle Capital Partners's GALT Position: Q2 2026 in Review

Argyle Capital Partners held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 13,375 shares worth $62.1K. The position accounts for 0.04% of the portfolio, ranked #177.

Argyle Capital Partners first reported a position in GALT in Q4 2024 and has held it in 7 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Argyle Capital Partners held 13,375 shares of Galectin Therapeutics worth $62.1K as of Q2 2026.
  • Argyle Capital Partners left its Galectin Therapeutics share count unchanged in Q2 2026.
  • Galectin Therapeutics made up 0.04% of Argyle Capital Partners's portfolio in Q2 2026, its #177 holding.
  • Argyle Capital Partners first reported a position in Galectin Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Argyle Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.